UAE peanut allergy treatment market report Size, Share, Growth Drivers, Trends, Opportunities & Forecast 2025–2030

UAE Peanut Allergy Treatment Market Overview

The UAE Peanut Allergy Treatment Market is valued at USD 15 million, based on a five-year historical analysis of the UAE food allergy market, where peanuts represent the largest and fastest-growing allergen segment . This growth is primarily driven by the increasing prevalence of peanut allergies among children and adults, heightened awareness regarding food allergies, improved diagnostic capabilities, and advancements in treatment options such as oral immunotherapy, biologic therapies, and epinephrine autoinjectors .

Dubai and Abu Dhabi are the dominant cities in the UAE Peanut Allergy Treatment Market due to their advanced healthcare infrastructure, high population density, and a growing number of specialty clinics focused on allergy treatments. The presence of international pharmaceutical companies and research institutions in these cities further enhances their market position .

In 2023, the UAE government implemented regulations mandating that all food products containing peanuts must clearly label their contents. This requirement is stipulated under the “UAE Food Safety Law, Federal Law No. 10 of 2015” issued by the Ministry of Climate Change and Environment, which enforces allergen labeling for packaged foods to improve consumer safety and awareness, thereby reducing the risk of allergic reactions among sensitive individuals .

UAE Peanut Allergy Treatment Market Segmentation

By Type:

The market is segmented into various treatment types, including Oral Immunotherapy (OIT), Epicutaneous Immunotherapy (EPIT), Injectable Epinephrine (e.g., autoinjectors), Antihistamines, Allergen-free food products, Emergency response kits, and Others. Among these, Injectable Epinephrine is the leading sub-segment due to its critical role in emergency situations and the increasing awareness of its importance in managing severe allergic reactions. Recent trends highlight growing adoption of oral immunotherapy and biologic therapies, alongside traditional emergency treatments .

By End-User:

The end-user segmentation includes Hospitals, Specialty allergy clinics, General clinics, Home care settings, Educational institutions, and Others. Hospitals are the leading end-user segment, primarily due to their comprehensive facilities and the availability of specialized medical staff to handle severe allergic reactions and provide ongoing treatment. Specialty allergy clinics are experiencing increased demand driven by rising awareness and the need for targeted therapies .

UAE Peanut Allergy Treatment Market Competitive Landscape

The UAE Peanut Allergy Treatment Market is characterized by a dynamic mix of regional and international players. Leading participants such as Aimmune Therapeutics, Inc. (a Nestlé Health Science company), DBV Technologies S.A., Allergy Therapeutics PLC, Nestlé Health Science, Sanofi S.A., Merck & Co., Inc., Pfizer Inc., Regeneron Pharmaceuticals, Inc., Takeda Pharmaceutical Company Limited, Novartis AG, GlaxoSmithKline plc, Johnson & Johnson, Bayer AG, AbbVie Inc., Viatris Inc. (EpiPen) contribute to innovation, geographic expansion, and service delivery in this space.

Aimmune Therapeutics, Inc.

2011


isbane, California, USA

DBV Technologies S.A.

2002

Paris, France

Allergy Therapeutics PLC

1999

Worthing, UK

Sanofi S.A.

1973

Paris, France

Merck & Co., Inc.

1891

Rahway, New Jersey, USA

Company

Establishment Year

Headquarters

Group Size (Large, Medium, or Small as per industry convention)

Revenue from Peanut Allergy Treatments (USD, UAE)

Market Share in UAE Peanut Allergy Segment (%)

Number of Treated Patients (UAE, annual)

Product Portfolio
eadth (number of peanut allergy SKUs)

Regulatory Approval Status (UAE Ministry of Health, FDA, EMA)

UAE Peanut Allergy Treatment Market Industry Analysis

Growth Drivers

Increasing Prevalence of Peanut Allergies:

The UAE has witnessed a significant rise in peanut allergies, with recent studies indicating that approximately 2.5% of children are affected. This translates to around 55,000 children in the UAE alone. The growing incidence is attributed to dietary changes and environmental factors, prompting a greater need for effective treatment options. As awareness of these allergies increases, healthcare providers are focusing on developing targeted therapies to address this urgent health concern.

Rising Awareness About Allergy Management:

Public awareness campaigns have led to a notable increase in the understanding of peanut allergies among the population. In future, it is estimated that over 75% of parents are aware of the symptoms and management strategies for peanut allergies. This heightened awareness is driving demand for specialized treatments and consultations, as families seek proactive measures to manage allergies effectively, thereby boosting the market for peanut allergy treatments in the UAE.

Advancements in Treatment Options:

The UAE is experiencing rapid advancements in peanut allergy treatments, including immunotherapy and biologics. In future, the introduction of new therapies is expected to increase treatment efficacy, with clinical trials showing a 35% improvement in desensitization rates. These innovations are attracting investment from pharmaceutical companies, enhancing the treatment landscape and providing patients with more effective management options, thus driving market growth significantly.

Market Challenges

High Cost of Treatment:

The financial burden of peanut allergy treatments remains a significant challenge in the UAE. The average annual cost for immunotherapy can exceed AED 35,000 per patient, which is prohibitive for many families. This high cost limits access to necessary treatments, particularly for lower-income households, thereby hindering overall market growth and leading to disparities in healthcare access across different socioeconomic groups.

Limited Availability of Specialized Healthcare Providers:

The UAE faces a shortage of healthcare professionals specializing in allergy management. Currently, there are only about 55 certified allergists in the country, which translates to approximately 1 allergist per 180,000 residents. This scarcity restricts patient access to specialized care and treatment options, creating a bottleneck in the healthcare system that can delay diagnosis and effective management of peanut allergies.

UAE Peanut Allergy Treatment Market Future Outlook

The future of the UAE peanut allergy treatment market appears promising, driven by ongoing advancements in medical research and technology. As the healthcare infrastructure expands, more patients will gain access to specialized care. Additionally, the increasing collaboration between local healthcare providers and international organizations is expected to enhance treatment options. With a focus on personalized medicine and digital health solutions, the market is poised for significant growth, addressing the rising demand for effective allergy management strategies in the region.

Market Opportunities

Development of New Therapeutic Solutions:

There is a growing opportunity for the development of innovative therapeutic solutions tailored to peanut allergies. With an estimated AED 250 million allocated for research and development in future, pharmaceutical companies are likely to invest in creating more effective treatments, which could significantly improve patient outcomes and expand market reach.

Expansion of Healthcare Infrastructure:

The UAE government is investing heavily in healthcare infrastructure, with plans to increase the number of specialized allergy clinics by 30% in future. This expansion will enhance access to care for patients suffering from peanut allergies, creating a favorable environment for market growth and improving overall health outcomes in the population.

Please Note: It will take 5-7 business days to complete the report upon order confirmation. Show more